Cargando…
Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action
Pancreatic islet β-cell dysfunction is characterized by defective glucose-stimulated insulin secretion (GSIS) and is a predominant component of the pathophysiology of diabetes. Imeglimin, a novel first-in-class small molecule tetrahydrotriazine drug candidate, improves glycemia and GSIS in preclinic...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894908/ https://www.ncbi.nlm.nih.gov/pubmed/33606677 http://dx.doi.org/10.1371/journal.pone.0241651 |